Evolution of drug-eluting biomedical implants for sustained drug delivery

Juliana C Quarterman; Sean M Geary; Aliasger K Salem

doi:10.1016/j.ejpb.2020.12.005

Back

Evolution of drug-eluting biomedical implants for sustained drug delivery

Journal article

Open access

Peer reviewed

Evolution of drug-eluting biomedical implants for sustained drug delivery

Juliana C Quarterman, Sean M Geary and Aliasger K Salem

European journal of pharmaceutics and biopharmaceutics, Vol.159, pp.21-35

02/2021

DOI: 10.1016/j.ejpb.2020.12.005

PMCID: PMC7856224

PMID: 33338604

Files and links (1)

url

https://doi.org/10.1016/j.ejpb.2020.12.005View

Published (Version of record) Open Access

Abstract

In the field of drug delivery, the most commonly used treatments have traditionally been systemically delivered using oral or intravenous administration. The problems associated with this type of delivery is that the drug concentration is controlled by first pass metabolism, and therefore may not always remain within the therapeutic window. Implantable drug delivery systems (IDDSs) are an excellent alternative to traditional delivery because they offer the ability to precisely control the drug release, deliver drugs locally to the target tissue, and avoid the toxic side effects often experienced with systemic administration. Since the creation of the first FDA-approved IDDS in 1990, there has been a surge in research devoted to fabricating and testing novel IDDS formulations. The versatility of these systems is evident when looking at the various biomedical applications that utilize IDDSs. This review provides an overview of the history of IDDSs, with examples of the different types of IDDS formulations, as well as looking at current and future biomedical applications for such systems. Though there are still obstacles that need to be overcome, ever-emerging new technologies are making the manufacturing of IDDSs a rewarding therapeutic endeavor with potential for further improvements.

Delayed-Action Preparations - administration & dosage

Delayed-Action Preparations - pharmacokinetics

Drug Approval - history

Drug Compounding - methods

Drug Compounding - trends

Drug Implants - administration & dosage

Drug Implants - history

Drug Implants - pharmacokinetics

Drug-Eluting Stents - history

History, 20th Century

History, 21st Century

Humans

United States

United States Food and Drug Administration

Details

Title: Subtitle: Evolution of drug-eluting biomedical implants for sustained drug delivery
Creators: Juliana C Quarterman - University of Iowa College of Pharmacy, Department of Pharmaceutical Sciences and Experimental Therapeutics, 180 S. Grand Avenue, Iowa City, IA 52242, United States
Sean M Geary - University of Iowa College of Pharmacy, Department of Pharmaceutical Sciences and Experimental Therapeutics, 180 S. Grand Avenue, Iowa City, IA 52242, United States
Aliasger K Salem - University of Iowa College of Pharmacy, Department of Pharmaceutical Sciences and Experimental Therapeutics, 180 S. Grand Avenue, Iowa City, IA 52242, United States. Electronic address: aliasger-salem@uiowa.edu
Resource Type: Journal article
Publication Details: European journal of pharmaceutics and biopharmaceutics, Vol.159, pp.21-35
DOI: 10.1016/j.ejpb.2020.12.005
PMID: 33338604
PMCID: PMC7856224
NLM abbreviation: Eur J Pharm Biopharm
ISSN: 0939-6411
eISSN: 1873-3441
Grant note: P30 CA086862 / NCI NIH HHS
Language: English
Date published: 02/2021
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
Record Identifier: 9984216725902771

Metrics

16 Record Views

56 Times Cited - Web of Science

See more details